Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Intel Strategy for Achieving Wealth and Off Topic -- Ignore unavailable to you. Want to Upgrade?

To: Dennis who wrote (15498)	1/2/1998 5:03:00 PM
From: Sonki	Read Replies (1) \| Respond to of 27012

rbot -do u know insiders? they reported 7m loss in rev vs 2m loss last year? i am not speculating. i bot efii which has had great earning report and one down turn. bot last week. =========================== from what i subsriber to this is a bait. Since trading at a high of $15 in early September, the stock has been in a downtrend the past four months, reaching a 52-week low of $7 3/4 just last week. In 1996, the company had revenues of just over $4 million and through the first three quarters of this year, it had sales of $4.5 million, an 81% increase from a year-ago. However, during this same period, the company had posted a loss of $7.1 million versus year-ago loss of $2.9 million. This latest FDA approval should help turn this latter trend around, however. ========================================================== SHORT-SELLING: What a great time it is to be a short-seller. Uncertainty and high valuations coupled with the ever-presence of speculative bulls, makes this a great market in which to make a quick buck with little downside. Probably the best sector to make these bear trades are in the biotechs. Give them an FDA approval or a licensing deal and the momentum guys take the bait almost every time-- sometimes running the stock up 50% or more in a matter of hours. Recent examples: On Dec. 24, Neoprobe (NEOP) shares leapt 25% to $10 on news the FDA approved the company's Investigational New Drug Application. The stock now trades at $6.50, or down 35%; Yesterday, shares of Computer Motion (RBOT) rose 45% on news the FDA gave market clearance to its robotic surgical arm. This morning, the stock has fallen as many as 2 5/16 points, or 20%. Not too long ago, one would at least have to wait for the nine-to-fivers (the guy who reads the story in the newspaper and is inspired to buy stk the next morning) to do their buying the next morning before being able to short at the peak. However, given the recent nervousness of the market, these buyers have been sitting on their hands. Momentum players have begun to recognize this and, therefore, have been less-apt to hold the trade for more than a day or two.